A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Multi-Layer Nano-Encapsulation

Vegalab's platform builds a particle in sequence rather than in one step: a payload core, then discrete biopolymer layers, up to 20, each selected for one job. The design question is never how many layers, it is which barrier each layer is being asked to solve.

Architecture

Conventional encapsulation gives a payload one shell and therefore one compromise between protection and release. A multiple-sphere construction separates those functions. An outer layer can be chosen for acid resistance or for mucoadhesion, a middle layer for controlled swelling and diffusion rate, an inner matrix for oxidation protection or protease exclusion. Because each layer is deposited on a defined precursor, the resulting release profile is a function of layer sequence and thickness rather than of a single polymer's properties. Vegalab manufactures the platform under GMP conditions in Korea, and the architecture is patent pending.

What the layers control

Four properties are engineered directly. First, stability: an oxygen and moisture barrier extends shelf life for labile actives such as thiols and reduced cofactors. Second, timing: pH-responsive and erosion-controlled layers shift release from stomach to intestine or spread it over hours. Third, contact: a mucoadhesive surface increases residence at the absorptive epithelium instead of being swept along. Fourth, compatibility: a hydrophilic exterior can disperse a lipophilic core in water without a cosolvent. None of these change the payload molecule itself.

What it does not do

Encapsulation does not raise a molecule's intrinsic membrane permeability, does not repeal molecular weight limits on transdermal passage, and does not convert an injectable peptide into a capsule by itself. For large hydrophilic payloads, protection from degradation is necessary but not sufficient, since absorption still requires a transport route. Honest program design pairs the carrier with a separate permeation strategy and measures the result rather than assuming it. Stated plainly: the platform protects, times and positions a payload. It does not rewrite the payload's physical chemistry, and any program that assumes otherwise will fail at the pharmacokinetic stage.

How a program runs

A feasibility study starts with the payload's molecular weight, logP, ionization, degradation route and target route of administration. Vegalab screens layer combinations, characterizes particle size distribution and encapsulation efficiency, and runs accelerated stability and in vitro release. Only then does an in vivo pharmacokinetic arm make sense, since a formulation that fails release testing will fail in an animal at greater cost. Deliverables at each step are a written report, the raw data and the methods, so a partner can hand the package to a regulator or a certifier without reconstructing the work. Decision gates sit between stages.

Key facts

The platform supports up to 20 programmable biopolymer layers around a single core (Vegalab SA technical disclosure, patent pending)
Enteric and pH-responsive coatings are established pharmacopeial technology for shifting release from stomach to intestine (USP <711> Dissolution; Ph. Eur. 2.9.3)
Pharmaceutical development should identify critical quality attributes, such as particle size, that affect release, and link them to formulation and process parameters (ICH Q8(R2))
Molecules above roughly 500 Da rarely cross intact skin in useful amounts, a limit that carriers do not remove (Bos and Meinardi 2000, Exp Dermatol 9:165)

How our delivery technology applies

The mechanism is layer assignment. Each barrier in a route gets its own layer instead of one shell compromising across all of them: acid resistance outside, mucoadhesion at the interface, diffusion control in the middle, oxidation exclusion at the core. That is why the same platform serves a thiol antioxidant, a lipophilic polyphenol and an essential oil, with different layer stacks and the same manufacturing line.

Ask for a feasibility scope on your payload and route.